What are the recommended washout intervals between the last dose of each phosphodiesterase‑5 inhibitor (avanafil, sildenafil, tadalafil) and administration of a nitrate in angina management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Accuracy Check: PDE5 Inhibitor-Nitrate Washout Intervals

Your stated intervals are PARTIALLY CORRECT but contain a critical error for avanafil.

Corrected Safe Intervals

Based on the most recent and authoritative guidelines, the recommended washout periods between PDE5 inhibitor use and nitrate administration are:

  • Avanafil: 12 hours ✓ CORRECT 1, 2, 3
  • Sildenafil: 24 hours ✓ CORRECT 4, 5, 6, 1, 2
  • Tadalafil: 48 hours ✓ CORRECT 4, 5, 6, 1, 2, 7
  • Vardenafil: 24 hours (you omitted this agent) 5, 1, 2

Evidence Hierarchy and Strength

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline provides the most current and definitive recommendations 1, 2. This supersedes older 2007 and 2013 guidelines that established the foundational intervals 4, 5, 6.

Key Guideline Statements:

The 2025 guideline explicitly states: "Avoid use of nitrates/nitroglycerin within 12 h of avanafil, 24 h of sildenafil/vardenafil, or 48 h of tadalafil" 1, 2. This represents a Class I contraindication based on the pharmacokinetic profiles and documented risk of profound hypotension, myocardial infarction, and death when these agents are combined 4, 5, 6.

FDA Drug Label Confirmation:

  • Tadalafil FDA label: "at least 48 hours should have elapsed after the last dose of tadalafil tablets before nitrate administration is considered" 7
  • Avanafil FDA label: "at least 12 hours should elapse after the last dose of avanafil before nitrate administration is considered" 3

Mechanism of Dangerous Interaction

All PDE5 inhibitors potentiate nitrate-induced vasodilation by inhibiting cyclic GMP degradation, leading to:

  • Profound hypotension (mean standing SBP drops of 28-36 mmHg documented) 6, 8
  • Risk of myocardial infarction from hypoperfusion 4, 6
  • Documented deaths in clinical practice 4, 6

The interaction duration correlates directly with drug half-life:

  • Sildenafil/vardenafil: ~4 hour half-life → 24-hour washout 9, 10
  • Tadalafil: 17.5 hour half-life → 48-hour washout 9, 8
  • Avanafil: shorter half-life → 12-hour washout 3, 11

Critical Clinical Caveats

Emergency Situations:

If a patient presents with acute coronary syndrome requiring nitrates after PDE5 inhibitor use, nitrates remain absolutely contraindicated within these time windows 1, 2, 7, 3. If nitrate administration becomes "medically necessary for a life-threatening situation" after the washout period, it should only occur "under close medical supervision with appropriate hemodynamic monitoring" 7, 3.

Common Pitfall:

The 2013 guidelines noted that for vardenafil, "the suitable delay before nitrate administration has not been determined, although blood pressure had generally returned to baseline by 24 h" 5. The 2025 guideline clarifies this to a definitive 24-hour interval, grouping vardenafil with sildenafil 1, 2.

Research Context:

A 2013 crossover study demonstrated that by 8 hours post-avanafil and 12 hours post-sildenafil, no significant BP/HR differences versus placebo were observed when NTG was administered 11. However, guidelines maintain conservative 12-hour and 24-hour intervals respectively for safety margins 1, 2.

Summary Table for Clinical Use

PDE5 Inhibitor Minimum Washout Before Nitrates
Avanafil 12 hours
Sildenafil 24 hours
Vardenafil 24 hours
Tadalafil 48 hours

Your original statement is accurate for the three agents listed but should include vardenafil (24 hours) for completeness.

References

Research

Cardiovascular effects of tadalafil.

The American journal of cardiology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.